Snowbird Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2011



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Drugs from Bugs: The Anti-Inflammatory Drugs of Tomorrow (Z1)


Organizer(s) Padraic G. Fallon, Grant McFadden and Amanda E.I. Proudfoot Fichard
April 3—7, 2011
Snowbird Resort • Snowbird, Utah USA
Abstract Deadline: Dec 2, 2010
Late Abstract Deadline: Jan 4, 2011
Scholarship Deadline: Dec 2, 2010
Early Registration Deadline: Feb 3, 2011

Supported by the Directors’ Fund


Summary of Meeting:
A recent global trend is that fewer novel therapeutics are progressing from the biopharmaceutical pipeline to the clinic. This has prompted the drug research and development sector to adopt less conventional approaches in broadening the search for new drugs. In this meeting we will examine the growing opportunities for discovery of novel drugs from pathogens, or the “drugs from bugs” approach. The genome of man is the product of the evolution of humans adapting to environmental factors, with infectious pathogens exerting potent selective pressure. Some of the major immune-mediated diseases of today are associated with genes that evolved to respond to pathogens. Novel therapeutic strategies and new drugs can be developed by both understanding how pathogens modulate and usurp the immune system, and also by identifying the functional molecules from pathogens. Indeed, a new generation of pathogen-derived immune modulating molecules is now in clinical trials. In this meeting leading experts will present the current status of the use of pathogens as a depository for new therapeutics. This forum will be an opportunity for industry to engage with academics for the development of novel strategies for drug discovery. This meeting will bring together cross-disciplinary scientists to exchange and share ideas, and thereby foster collaborations on the generation of new drug strategies for the future.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, APRIL 3

15:00—19:30
Registration

Ballroom Lobby
18:15—19:15
Refreshments

Ballroom Lobby
19:15—20:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
* Grant McFadden, University of Florida, USA

Jose-Carlos Gutierrez-Ramos, Pfizer, Inc, USA
Anti-Inflammatory Drugs: The Path from Discovery to the Clinic

19:15—20:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Ballroom 2
Albert B. Seymour, Shire HGT, USA
Human Genetic Approaches to Biotherapeutics: Target ID to Patient Enrichment


MONDAY, APRIL 4

07:00—08:00
Breakfast

Golden Cliff/Eagles
08:00—11:00
Immune Modulating Molecules from Pathogens
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
Antonio Alcami, Centro de Biologia Molecular Severo Ochoa, Spain
Therapeutic Exploitation of Viral Chemokine Modulators

* Grant McFadden, University of Florida, USA
When the Bug is the Drug: Exploiting Poxviruses for Oncolytic Virotherapy

William Harnett, Strathclyde Institute for Pharmacy and Biomedical Sciences, UK
The Path from a Pathogen Molecule to Synthetic Anti-Inflammatory Mimetics: The ES-62 Story

Paola Zaccone, University of Cambridge, UK
Short Talk: The S. mansoni Glycoprotein Omega-1 Induces Foxp3 Expression in NOD Mouse CD4+ T Cells

08:00—11:00
Evolving Strategies for Screening and Early Lead Identification
Meeting has ended...abstracts no longer viewable online.

Ballroom 2
Timothy A. Grese, Lilly Research Laboratories, USA
PD2: New Collaborative Models for Early Stage Drug Discovery

Robert J. Gould, Fulcrum Therapeutics, USA
Protein Methyl Transferase Inhibitors: Targeted Therapeutics for Targeted Patients

Miles Congreve, Heptares Therapeutics Ltd, UK
Fragment-Based Screening Approaches to GPCR Targets

Linda Brady, NIMH, National Institutes of Health, USA
Probe Development within the Molecular Libraries Probe Production Centers Network (MLPCN): Leads for Drug Development from Previously Intractable Targets

Peter L. Toogood, Lycera Corporation, USA
Short Talk: Autoimmune Disease Modification through Mitochondrial Bioenergetics

09:20—09:40
Coffee Break

Ballroom Lobby
11:00—13:00
Poster Setup

Superior/Superior Lobby/Wasatch/Maybird
13:00—22:00
Poster Viewing

Superior/Superior Lobby/Wasatch/Maybird
11:00
On Own for Lunch and Recreation

14:30—16:30
Workshop 1: Recent Advances in Drug Discovery from Pathogens

Ballroom 3
* Alexandra Lucas, University of Florida, USA

Mattias Collin, Lund University, Sweden
Bacterial Enzymes Hydrolyzing Antibody Glycans as a Novel Anti-Inflammatory Therapeutic Principle

Christian Rueter, Universität Münster, Germany
’From Saulus to Paulus ’: A Pathogen-Derived Cell-Penetrating Immune Modulator for the Treatment of Inflammatory Bowel Diseases

Miguel A. Pineda, Institute of Infection Immunity and Inflammation, UK
Investigation of Whether the Filarial Nematode Product ES-62 Ameliorates Collagen-Induced Arthritis by Targeting the IL-17 Inflammatory Axis

Lothar Steidler, ActoGeniX, Belgium
Prevention of Experimental Oral Mucositis in Hamsters by a Mouth Rinse Formulation with Human Trefoil Factor 1-Secreting Lactococcus lactis

Mordechay Gerlic, Sackler Faculty of Medicine, Tel Aviv University, Israel
Vaccinia Virus F1L Protein Inhibits NLRP1 Inflammasome Activation and Promotes Virulence

Maria L. Higuchi, São Paulo University School of Medicine, Brazil
Trans-Sialidase from Trypanosoma Cruzi : An Anti-Atherosclerotic Drug

16:30—17:00
Coffee Available

Ballroom Lobby
17:00—19:15
Pathogen Modulators of Immune-Mediated Diseases
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
* Anne Cooke, University of Cambridge, UK
Modulation of Autoimmunity by Pathogen Derived Molecules

Cathryn Nagler, University of Chicago, USA
The Commensal Microbiota and the Regulation of Allergic Disease

Sarkis K. Mazmanian, California Institute of Technology, USA
Exploiting Commensal Immune Modulation for New Drugs

Padraic Fallon, Trinity College Dublin, Ireland
Who Needs Anti-Inflammatory Drugs when a Bug will Do?

17:00—19:00
Novel Approaches and Technology for Early Stage Drug Discovery
Meeting has ended...abstracts no longer viewable online.

Ballroom 2
Bryan Roth, University of North Carolina, Chapel Hill, USA
Identifying New Molecular Targets for Known Drugs

Daniel A. Engel, University of Virginia, USA
A General Approach to Novel Drug Target Identification using Budding Yeast

Jolanta Ewa Grembecka, University of Michigan, USA
Short Talk: A Strategy to Develop Potent Inhibitors of Protein-Protein Interaction: Targeting Menin-MLL Interaction in Leukemia

19:00—20:00
Social Hour with Lite Bites

Superior/Superior Lobby/Wasatch/Maybird
19:30—22:00
Poster Session 1

Superior/Superior Lobby/Wasatch/Maybird

TUESDAY, APRIL 5

07:00—08:00
Breakfast

Golden Cliff/Eagles
08:00—11:00
Clinical Perspective/Development
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
Alexandra Lucas, University of Florida, USA
Viral Bugs Make Great Drugs

* Amanda E.I. Proudfoot Fichard, Merck Serono Geneva Research Centre, Switzerland
Parasite Derived Anti-Inflammatory Drugs

Wynne Weston-Davies, Varleigh Immuno Pharmaceuticals Ltd., UK, UK
Clinical Trials of Arthropod-Derived Proteins

08:00—11:00
Drug Discovery in Academia
Meeting has ended...abstracts no longer viewable online.

Ballroom 2
Dennis C. Liotta, Emory University, USA
The Role of CXCR4 Modulators in Controlling HIV Entry, Inflammation and Certain Types of Cancer

P. Jeffrey Conn, Vanderbilt University School of Medicine, USA
Partnering with Big Pharma to Develop mGluR Allosteric Modulators for CNS Disorders: From HTS to Clinical Candidates

Julian Blagg, Institute of Cancer Research, UK
Novel Cancer Therapeutics Developed through Academic-Industrial Partnerships

Craig W. Lindsley, Vanderbilt University, USA
Allosteric Modulation of Muscarinic Receptors for Treatment of Schizophrenia and Alzheimer's Disease

Soumya S. Ray, Schrödinger, USA
Short Talk: Screening and Identification of Small Molecules Against Targets Related to Neurodegenerative Diseases

09:20—09:40
Coffee Break

Ballroom Lobby
13:00—22:00
Poster Viewing

Superior/Superior Lobby/Wasatch/Maybird
11:00
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Ballroom Lobby
17:00—19:00
Structure-Function Analysis of Therapeutic Pathogen Molecules
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
Jos van Strijp, University Medical Center Utrecht, Netherlands
Anti-Inflammatory Drugs from Staphylococcus aureus

Leah A. Couture, University of Maryland School of Medicine, USA
Short Talk: Identification of Protein-Protein Interfaces Involved in TLR2 and TLR4 Signaling using Cell-Penetrating TIRAP Decoy Peptides

Tracy M. Handel, University of California, San Diego, USA
Chemokin Structure-Function Mimicy/Exploratory by Virus

* Daved Fremont, Washington University School of Medicine, USA
Structural Mechanisms of Viral Immune Evasion

17:00—19:00
Imaging and Biomarkers in Early Stage Discovery
Meeting has ended...abstracts no longer viewable online.

Ballroom 2
Cyrille Sur, Merck Research Laboratories, USA
Small Molecule Biomarkers in Drug Discovery: Optical and PET Imaging Approaches

Jacob M. Hooker, Harvard Medical School, USA
Advances in Radiotracer Chemistry for Use in Positron Emission Tomography

Javier Sanz, Mount Sinai School of Medicine, USA
New Approaches for Imaging of Atherosclerotic Cardiovascular Disease

Nicholas A. Malmquist, Institut Pasteur, France
Short Talk: Targeting Epigenetic Regulation in the Treatment of Malaria

19:00—20:00
Social Hour with Lite Bites

Superior/Superior Lobby/Wasatch/Maybird
19:30—22:00
Poster Viewing

Superior/Superior Lobby/Wasatch/Maybird

WEDNESDAY, APRIL 6

07:00—08:00
Breakfast

Golden Cliff/Eagles
08:00—11:00
Pathogen Modulation of Inflammatory Signaling
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
Victor Nizet, University of California, San Diego School of Medicine, USA
Probing Bacterial-Phagocyte Interactions for Novel Infectious Disease (and Anti-Inflammatory?) Therapeutics

Kate A. Fitzgerald, University of Massachusetts Medical School, USA
Sensing from Within: Cytosolic Sensing of Microbial Pathogens

* Luke A. J. O'Neill, Trinity Biomedical Sciences Institute, Ireland
Therapeutic Targeting of Toll-Like Receptors

Maria Elena de Lima, Federal University of Minas Gerais, Brazil
Possible Novel Drugs from Arthropod Venoms

08:00—11:00
Emerging Targets and Approaches in Drug Discovery
Meeting has ended...abstracts no longer viewable online.

Ballroom 2
H. Alex Brown, Vanderbilt University, USA
Phospholipase D: Discovery and Development of Isoform Selective PLD Inhibitors for the Treatment of Cancer

Dinah Sah, Voyager Therapeutics, USA
siRNA Therapeutics: Overview and Clinical Trial Update

Mark Layton, Merck Research Laboratories, USA
Discovery of Oral Allosteric Akt Kinase Inhibitors for the Treatment of Cancer: MK-2206 and Beyond

James A. Wells, University of California, San Francisco, USA
Site-Directed Drug Discovery for Challenging Targets

09:20—09:40
Coffee Break

Ballroom Lobby
11:00
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Ballroom Lobby
17:00—19:00
Screening Strategies/Technologies- Recent Advances
Meeting has ended...abstracts no longer viewable online.

Ballroom 3
* Antonio Alcami, Centro de Biologia Molecular Severo Ochoa, Spain

Colin Macaulay, Viron Therapeutics Inc., Canada
From Pathogen Immunomodulators to Novel Drugs

Megan Hogan, U. S. Army Medical Research, USA
Short Talk: Toward the Development of Orthopoxvirus Phosphatase Inhibitors

Reto Stöcklin, Atheris Laboratories, Switzerland
Venomics: Targeted Drug Discovery and Lead Optimisation using Animal Venoms

17:00—19:00
Evolving Role of Big Pharma and Biotech
Meeting has ended...abstracts no longer viewable online.

Ballroom 2
Juswinder Singh, Celgene Corporation, USA
Bruton’s Tyrosine Kinase from Bench to Bedside: Covalently Silencing B Cells with AVL-292

Dimitri E. Grigoriadis, Neurocrine Biosciences, Inc., USA
Innovation and the Future of Novel Drug Discovery in Biotech

19:00—20:00
Social Hour with Lite Bites

Ballroom 1
20:00—23:00
Entertainment

Ballroom 1

THURSDAY, APRIL 7

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13AI094907-01




We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Pfizer Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676